Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar:156:120-126.
doi: 10.1016/j.radonc.2020.11.033. Epub 2020 Dec 5.

Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion

Pablo Munoz-Schuffenegger  1 , Aisling Barry  1 , Eshetu G Atenafu  2 , John Kim  1 , James Brierley  1 , Jolie Ringash  1 , Anthony Brade  1 , Robert Dinniwell  1 , Rebecca K S Wong  1 , Charles Cho  1 , Tae Kyoung Kim  3 , Gonzalo Sapisochin  4 , Laura A Dawson  5
Affiliations

Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion

Pablo Munoz-Schuffenegger et al. Radiother Oncol. 2021 Mar.

Abstract

Background: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MVI) is associated with a poor prognosis. The purpose of this study is to describe long-term outcomes of patients with HCC and MVI treated with stereotactic body radiation therapy (SBRT).

Methods: Patients with HCC and MVI who were treated with SBRT from January 2003 to December 2016 were analyzed. Patients who had extrahepatic disease or previous liver transplant were excluded. Demographical, clinical, and treatment variables were analyzed.

Results: 128 eligible patients with HCC and MVI were treated with SBRT. Median age was 60.5 years (39 to 90 years). Baseline Child-Pugh (CP) score was A5 in 67%, A6 in 20%. Median SBRT dose was 33.3 Gy (range: 27 to 54 Gy) in 5 fractions. Local control at 1 year was 87.4% (95% CI 78.6 to 96.1%). Median overall survival (OS) was 18.3 months (95% CI 11.2 to 21.4 months); ECOG performance status > 1 (HR:1.85, p = 0.0138) and earlier treatment era (HR: 2.20, p = 0.0015) were associated with worsening OS. In 43 patients who received sorafenib following SBRT, median OS was 37.9 months (95% CI 19.5 to 54.4 months). Four patients developed GI bleeding possibly related to SBRT at 2 to 8 months, and 27% (31/112 evaluable patients) had worsening of CP class at three months after SBRT.

Conclusions: SBRT was associated with encouraging outcomes for patients with HCC and MVI, especially in those patients who received sorafenib after SBRT. Randomized phase III trials of SBRT with systemic and/or regional therapy are warranted and ongoing.

Keywords: Stereotactic Body Radiation Therapy, SBRT; hepatocellular carcinoma; macrovascular invasion; sorafenib.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Laura. A. Dawson reports patent/License Fees/Copyright: Raysearch.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources